A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 381,382 shares of BGNE stock, worth $77.9 Million. This represents 0.15% of its overall portfolio holdings.

Number of Shares
381,382
Previous 381,382 -0.0%
Holding current value
$77.9 Million
Previous $54.4 Million -0.0%
% of portfolio
0.15%
Previous 0.15%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$129.52 - $174.32 $49.4 Million - $66.5 Million
381,382 New
381,382 $54.4 Million

Others Institutions Holding BGNE

About BeiGene, Ltd.


  • Ticker BGNE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,700,000
  • Market Cap $21.2B
  • Description
  • BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...
More about BGNE
Track Steven Cohen's Portfolio

Track Steven Cohen Portfolio

Follow Steven Cohen (Point72 Asset Management, L.P.) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.